SEATTLE, Oct. 03, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing Lexaria Biosciences Inc. (CSE: LXX) (LXX: CN) (CNSX: LXX) (OTCQX: LXRP). The company has developed an innovative drug delivery platform that increases intestinal absorption rates, rapidly delivers active ingredients to the bloodstream, and provides taste-masking benefits.

The cannabis industry is heating up with the legalization of medical and recreational cannabis across Canada and a growing number of states. While cannabis flower has been the early focus, cannabinoid-infused edibles and concentrates represent the fastest growing segments of the $100+ billion industry.

Absorption is one of the most important differentiators for both medical and recreational cannabis products. Medical cannabis patients want to receive a standardized dose and consistent effect each time, while recreational consumers want to experience a high as quickly as possible.

“We are focused on making ingestible or edible bioactive substances taste better, smell better, act faster and enhance potency,” says Lexaria President John Docherty, a trained pharmacologist and toxicologist, who is also the former president and chief operation officer of Helix BioPharma Corp.

Internal R&D vs. Outsourcing

Many cannabis companies plan to launch cannabis-infused products over the coming year. In fact, the alcohol industry has been so concerned about the potential for these products that giants like Constellation Brands Inc. and Molson Coors Brewing Co. have made significant investments.

With the race to develop alternative cannabis products, many cannabis companies have a choice between developing internal delivery platforms or partnering with experts to develop top-performing products. Internal develop involves a high cost and potentially lengthy delays but provides flexibility, while partnerships can provide speed to market and a known solution at a predetermined cost.

Lexaria Biosciences’ innovative drug delivery platform enables cannabis absorption in just 10 to 20 minutes compared to the 60 to 120 minutes for many cannabis edibles on the shelves today. The technology also represents an alternative to sugars and chemicals that are often used to mask flavors. Lexaria was one of the first to offer these solutions to the cannabis industry.

The company has already licensed its products to numerous cannabis companies. For example, the company’s customers include the maker of the 1906 brand of cannabis-infused chocolates in Colorado, a Canadian-based developer of cannabis wines and beers, and a new Canadian company focused on cannabis-infused edibles.

Clinically Proven Advantages

Lexaria’s DehydraTECH platform has shown tremendous promise in several different clinical studies. By combining cannabinoids with fatty acid oil, applying food carrier particles, and performing a dehydration procedure, the technology masks the earthy taste of cannabis and delivers it more effectively.

Earlier this year, the company released the results of a randomized, placebo-controlled, double-blind European human clinical study that evaluated TurboCBD—a proprietary DehydraTECH  powered CBD hemp oil capsule—showing 317% greater absorption at the 30 minute mark and higher blood concentration. Lexaria is one of very few companies anywhere in the world to have completed human clinical studies related to cannabinoids and have proven that its technology is effective.

The company conducted similar studies of DehydraTECH’s potential with other active ingredients, such as nicotine. In an in-vivo animal study, researchers delivered DehydraTECH powered nicotine in an edible form into blood plasma in just minutes after dosing with 90.2 percent greater delivery than control after just 10 minutes. Lexaria is one of the only companies in the world with technology proven effective in both the nicotine and cannabis industries.

Looking Ahead

Lexaria’s growing portfolio of more than 50 patents has expanded its drug delivery platform well beyond cannabis, including vitamins, NSAIDs, nicotine, and other molecules. Management plans to develop the patent portfolio into 150 to 200 patent applications around the world within two years.

Investors interested in capitalizing on the burgeoning cannabis industry along with additional potential across other multi-billion dollar markets may want to take a closer look at the company ahead of further partnerships and announcements.

For more information, visit the company’s website or download their investor presentation.

Please follow the link to read the full article:


The above article is sponsored content. Emerging Growth LLC, which owns and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation:

About CFN Media

CFN Media (CannabisFN) is the leading agency and financial media network dedicated to the global cannabis industry, helps companies operating in the space attract investors, capital, and publicity. Since 2013, private and public cannabis companies in the US and Canada have relied on CFN Media to grow and succeed.

Learn how to become a CFN Media client company, brand or entrepreneur:

Download the CFN Media iOS mobile app to access the world of cannabis from the palm of your hand:

Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone:

Disclaimer is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on (the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate., a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies.  We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. received compensation for producing and presenting high quality and sophisticated content on along with financial and corporate news.  

The above article is sponsored content. Emerging Growth LLC, which owns and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation:

Frank Lane